A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors
详细信息 查看全文
- 作者：Y. Shinkoda ; A. Shirahata ; K. Fukutake ; J. Takamatsu ; M. Shima ; H. Hanabusa ; H. Mugishima ; H. Takedani ; K. Kawasugi ; M. Taki ; T. Matsushita ; A. Tawa ; K. Nogami ; S. Higasa ; Y. Kosaka ; T. Fujii ; M. Sakai ; M. Migita ; M. Uchiba ; K. Kawakami ; K. Sameshima ; Y. Ohashi and H. Saito
- 刊名：Haemophilia
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：23
- 期：1
- 页码：59-66
- 全文大小：160K
- ISSN：1365-2516
文摘
MC710, a 1:10 protein weight ratio mixture of plasma-derived activated factor VII (FVIIa) and factor X (FX), is a novel bypassing agent for haemostasis in haemophilia patients with inhibitors. We evaluated the haemostatic efficacy and safety of one to two administrations of MC710 in 21 joint, muscle, and subcutaneous bleeding episodes in 14 male patients, in a multi-centre, open-label, non-randomized clinical trial.